










































Treatable traits and therapeutic targets
Citation for published version:
Russell, C & Baillie, J 2017, 'Treatable traits and therapeutic targets: goals for systems biology in infectious
disease' Current Opinion in Systems Biology, vol. 2, pp. 140-146. DOI: 10.1016/j.coisb.2017.04.003
Digital Object Identifier (DOI):
10.1016/j.coisb.2017.04.003
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Current Opinion in Systems Biology
Publisher Rights Statement:
© 2017 The Author(s). Published by Elsevier Ltd. This is an  open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Available online at www.sciencedirect.com
ScienceDirect
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Systems BiologyTreatable traits and therapeutic targets: Goals for
systems biology in infectious disease
Clark D. Russella and J. Kenneth Bailliea,bAbstract
Among the many medical applications of systems biology, we
contend that infectious disease is one of the most important
and tractable targets. We take the view that the complexity of
the immune system is an inevitable consequence of its evo-
lution, and this complexity has frustrated reductionist efforts to
develop host-directed therapies for infection. However, since
hosts vary widely in susceptibility and tolerance to infection,
host-directed therapies are likely to be effective, by altering the
biology of a susceptible host to induce a response more similar
to a host who survives. Such therapies should exert minimal
selection pressure on organisms, thus greatly decreasing the
probability of pathogen resistance developing.
A systems medicine approach to infection has the potential to
provide new solutions to old problems: to identify host traits
that are potentially amenable to therapeutic intervention, and
the host immune factors that could be targeted by host-
directed therapies. Furthermore, undiscovered sub-groups
with different responses to treatment are almost certain to exist
among patients presenting with life-threatening infection, since
this population is markedly clinically heterogeneous. A major
driving force behind high-throughput clinical phenotyping
studies is the aspiration that these subgroups, hitherto opaque
to observation, may be observed in the data generated by new
technologies. Subgroups of patients are unlikely to be static –
serial clinical and biological phenotyping may reveal different
trajectories through the pathophysiology of disease, in which
different therapeutic approaches are required.
We suggest there are two major goals for systems biology in
infection medicine: (1) to identify subgroups of patients that
share treatable features; and, (2) to integrate high-throughput
data from clinical and in vitro sources in order to predict trac-
table therapeutic targets with the potential to alter disease
trajectories for individual patients.
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Infection is the largest single cause of death in humans
worldwide and many infectious agents provide relevant
in vitromodel systems that are both amenable to study with
high-throughput techniques, and recapitulate key events
in disease pathogenesis. In this review, we consider how
systems biology approaches may be leveraged to address
the major unmet needs in infection medicine in the 21st
century, with the aim of improving outcomes for patients
with infection. In clinical practice we are unable to thera-
peutically modulate the host immune response to infec-
tion, largely due to its inevitable complexity. Despite this,
we contend that host-directed therapies have a high
probability of success, since there is already considerable
innate variation in host responses to infectious disease,
ranging from extreme susceptibility, to complete resis-
tance, and tolerance. Infectious diseases are survivable if
you have the right genetics. The challenge is to make the
same diseases survivable for patients who would otherwise
succumb.
A systems medicine approach to infection has the po-
tential to combine and integrate relevant signals from
clinical, genomic, transcriptomic, proteomic and path-
ogen biology data to draw inferences about disease
pathogenesis. Below we discuss examples of aspects of
this approach applied to various infectious diseases, and
suggest future goals for the application of systems
biology to infection medicine.
Unmet needs for treating patients with infection
More than 70 years after the discovery of penicillin [1],
this same drug is still a prominent weapon in our anti-
bacterial armamentarium. More broadly, the concept
underlying this therapeutic approach - attempting to
eradicate the pathogen from a patient’s body using
antimicrobial drugs - remains the only effective treat-
ment. Although spectacularly successful, the focus on
the pathogen has two limitations.
Firstly, death frequently occurs in infectious disease
despite effective antimicrobial therapy. Alongside the





Therapeutic intervention to modulate an aspect
of the host response to infection to alter the
biology of a susceptible host to induce a
response more similar to a host who survives.
Clinical
syndrome
A collection of clinical symptoms and signs that
tend to occur together. Depth of characterisation
is limited by the range of observations available.
Disease A clinical syndrome for which at least some of the
underlying pathophysiological processes are
thought to be known.
Subgroup A smaller set within any population of patients,
who are linked by some clinical feature or group
of features.
Endotype A subgroup within a population of patients who
are distinguished by a shared disease process.
Treatable trait The pathophysiological feature (or, in a looser
sense, a biomarker or group of biomarkers for
that feature) that determines whether a given
therapy will improve a given patient’s outcome.
The same trait may be present in many different
clinical syndromes or disease processes.
140 Cancer and systemic diseases (2017)damage is also caused by the host immune response.
Immune-mediated damage leading to respiratory, car-
diovascular and renal failure (sepsis) continues even
after eradication of the pathogen [2]. At present, no
treatments exist to modify these deleterious aspects of
the host immune response.
Secondly, antimicrobial resistance threatens to liberate
pathogens from the range of our solitary weapon against
them. Unless something changes, deaths from infection
are predicted to soar, overtaking malignant disease even
in developed countries by 2050 [3].
Therapies to modulate the host response to infection
would have the theoretical advantage that, in addition to
promoting survival in the presence of effective antimi-
crobials, a host-targeted therapy may exert a less
powerful selection pressure on pathogens, and may be
more difficult for a pathogen to evolve to overcome. In
our view, the development of such therapies is well-
suited to the application of systems approaches.
Inevitable complexity of the immune system
The human immune system is arguably the most
complicated organ system in the body, encompassing
numerous effectors, inter-related feedback loops and
extensive redundancy. This complexity is unsurprising
when considering that our immune system has evolved
in the face of microbial virulence factors that directly
interfere with regulatory and effector mechanisms.Current Opinion in Systems Biology 2017, 2:139–145Examples of microbial interference with host immune
mechanisms are numerous and diverse. For example,
one of the first innate immune mechanisms encoun-
tered by many pathogens is phagocytosis, which serves
to both prime the adaptive response and eliminate
invading pathogens by intracellular killing. Pathogenic
Yersinia species, a group of facultative intracellular
pathogens, encode a type three secretion system to
directly inject effector proteins into the host cell cyto-
plasm, modulating the cytoskeleton to prevent phago-
cytosis, and inducing apoptosis of immune cells and
blocking the MAPK and NF-kB pathways to reduce
cytokine production [4]. Another bacterium, Pseudo-
monas aeruginosa, secretes a protease that cleaves a host
protein (corticosteroid-binding globulin) to release the
corticosteroid hormone cortisol at the site of initial
infection, incapacitating the local innate immune
response [5]. Even the relatively tiny genome of the
influenza A virus encodes a protein (NS1) which is non-
essential for replication and seems to be dedicated to
interfering with both the induction and action of the
host antiviral interferon response by sequestering viral
dsRNA, preventing activation of RIG-1 signalling and
inhibiting protein kinase R and OAS/RNase L [6].
The adaptive response, mediated by T and B lympho-
cytes, is also a target. The human immunodeficiency
virus encodes three proteins that each down-regulate
cell surface MHC-1 expression by distinct mecha-
nisms, preventing MHC-I signalling to activate the
cytotoxic T-cell response to virus-infected cells [7]. To
prevent B-cells mounting an antibody response to
infection, the Staphylococcus aureus surface protein A
binds to the Fc-g portion of antibodies [8].
These examples cover a few of the mechanisms patho-
gens have evolved to extensively interfere with the host
immune response. The animal innate immune system is
thought to have evolved over 1000 million years, starting
with amebae able to phagocytose external material for
nutrition [9]. The adaptive immune system in mammals
is thought to have arisen 500 million years ago in fish
[10]. Since these initial events, the immune system in
each host species has participated in a genetic arms race,
evolving alongside relentless exposure to these micro-
bial immune interference strategies from innumerable
pathogens. Furthermore, the immune system must
successfully distinguish self from non-self antigens, with
deleterious consequences arising (i.e. autoimmune dis-
ease) when this fails. The requirement to overcome
these microbial immune interference strategies whilst
preserving the recognition of self-antigens has provided
the necessary pressure to drive the human immune
system to evolve into a hugely complex organ system. In
the context of this inevitable complexity, it is no surprise
that reductionist approaches to development of host-
targeted therapies in infectious disease have largelywww.sciencedirect.com
Systems biology in infectious disease Russell and Baillie 141failed. A systems medicine approach may offer signifi-
cant advantages.
It is reasonable to expect that as-yet undiscovered
therapeutic interventions could alter the host immune
response to promote survival. We infer this from the
simple fact that some hosts do better than others when
confronted with the same pathogen: the host response
to infection is, in all cases that we know to have been
studied, heterogeneous. Furthermore, much of this
variation is heritable [11]. We conclude that host factors
exist that promote survival from specific infections, and
that these must vary between individuals, and hence
that it should be possible to identify and utilise these
factors therapeutically to alter the biology of a suscep-
tible host to induce a response more similar to a host
who survives. The scale of the challenge of finding these
targets is such that it is hard to imagine a solution being
found without the power of systems approaches [12].
Conceptually, this could involve promoting resistance to
(suppressing pathogen replication), or tolerance of
(preventing damage associated with immune response
to pathogen), an infecting pathogen [13]. Although
theoretically attractive as a tool to limit damage to the
host [14], inducing tolerance is not without potential
dangers: a sustained high pathogen load could facilitate
transmission (iatrogenic super-shedders) and, perhaps
more worryingly in emerging zoonotic infections, pro-
vide the time required for the selection of mutants with
better host adaptation.
Current failings in targeting the host
Due to their reliable and broad acting anti-inflammatory
effects, corticosteroids represent an intuitively attrac-
tive strategy to reduce inflammation during infection.
Indeed, a survival benefit has been demonstrated in a
small number of uncommon infections (bacterial men-
ingitis, tuberculous meningitis and pericarditis, hypo-
xaemic Pneumocystis jiroveci pneumonia) [15]. In contrast,
there is uncertainty over safety and benefit in other
infections (e.g. RSV bronchiolitis) and clear evidence of
harm in others (viral hepatitis, cerebral malaria, influ-
enza virus, SARS coronavirus, HIV-associated Crypto-
coccal meningitis) [15e19].
A more specific host-directed therapy, recombinant
human activated protein C (rhAPC), was licensed for
treatment of severe sepsis based on the results of a
single clinical trial [20]. rhAPC has anti-inflammatory
and anti-thrombotic properties, and circulating levels
are low in patients with sepsis [21]. Sadly, a subsequent
trial in an overlapping patient group showed a trend
towards increased mortality [22]. A third trial, mandated
by the regulatory authorities, did not detect any mor-
tality benefit, and the drug was quickly withdrawn from
the market [23].www.sciencedirect.comThese negative trial results in sepsis are not necessarily
conclusive. The heterogeneity of the host response,
and the diverse range of microbes involved, means that
amongst all patients with sepsis (itself an unrealisti-
cally broad syndrome) there are likely to be numerous
biologically-different sub-groups, with distinct immune
responses and more importantly, different risk: benefit
balance for a given therapy. Corticosteroids, for
example, may save some patients but harm others. Our
current understanding of infection does not allow
clinical differentiation of these sub-groups, so poten-
tially beneficial therapies may be falsely rejected in
clinical trials. We believe that a major output of sys-
tems approaches to infection will be the elucidation of
previously hidden therapeutically-important sub-
groups of patients who share a ‘treatable trait’ (i.e.
response to therapy).
High-dimensionality data from patients
We have discussed two central problems in infection
medicine. Firstly, the development of therapies to
modulate the host immune response is impeded by the
inevitable complexity of the human immune system.
Secondly, the range and degree of characterisation of
clinical syndromes in medicine is constrained by the
range of observations that are available; we likely fail to
identify sub-groups of patients with treatable traits due
to a paucity of relevant observations. The promise of
systems approaches to infection medicine is that new
technologies may provide solutions to these old prob-
lems. Large-scale biological data-sets from an increasing
range of high-throughput technologies are becoming
available, including (but not limited to) high-resolution
transcriptional profiling [24], mass spectrometry-based
proteomics [25] and metabolomics, genome-scale
CRISPR-Cas9 knockout screening [26], and whole
genome sequencing/genome-wide association studies.
These modalities could provide new, biologically
important observations that have not previously been
observed in patients. It is very likely that some of these
observations will be directly relevant to clinical man-
agement e the challenge will be to identify the ones
that matter.
There are three broad categories of clinical utility for
these new data sources in infection medicine:
 identifying treatable traits and therapeutically-
relevant subgroups;
 identifying new therapeutic targets in the immune
response; and,
 improving prognostication.The value of prognostication in current clinical prac-
tice is, in our view, limited by the range of therapeutic
options. Put simply, it is only useful to predict theCurrent Opinion in Systems Biology 2017, 2:139–145
142 Cancer and systemic diseases (2017)future if you have some capacity to change it. Partic-
ularly in the case of acute and immediately life-
threatening infection, our range of therapeutic op-
tions is very limited, regardless of the degree of cer-
tainty attached to the prognosis, therefore we suggest
the first two applications should be prioritised. In
contrast, the identification of syndromes (collections of
clinical observations that tend to occur in patients
suffering the same disease) has been the primary
mechanism for progress in the understanding of human
disease since long before the time of Hippocrates [27].
Finding a syndrome is the first step towards identifying
the common biological processes that define a disease,
and ultimately to identifying effective treatments.
We hope that the application of systems technologies
will help us define treatable traits in infection,
thus providing a starting point for new therapeutic
interventions (Figure 1).
Treatable traits and therapeutically-relevant
subgroups
Importantly, a systems model of the disease process
need not predict every transcript and metabolite in theFigure 1
Summary of a systems medicine approach to infection. A wide range of data s
fundamental goals – clinically-informative phenotyping of patients, and identi
Current Opinion in Systems Biology 2017, 2:139–145massively multi-dimensional datasets generated by new
technologies. The primary challenge is instead to iden-
tify those components of inter-host variation that are
amenable to intervention; the evidence of disease pro-
cesses that we can change. This is Agusti’s concept of
“treatable traits” [28], a term coined in the field of
chronic obstructive lung disease but no less relevant
here.
A computational model of infection could therefore
include not only traditional measures of pathogen
burden and evidence of systemic injury [29], but also
independent components of the immune response or
the metabolic consequences, detected using high-
throughput technologies. The behaviour of the whole
system may be impenetrably complex, but the compo-
nents required to predict the effect of an intervention
may be far simpler. The trajectory followed by each
patient along an informative set of vectors may reveal
different groups of patients that appear clinically similar,
and may even have similar outcomes, but different dis-
ease processes (Figure 2). By mapping the “flight path”
of each patient through disease, we anticipate thatources can be combined using various methods (see text) to achieve two
fication of therapeutic targets.
www.sciencedirect.com
Figure 2
Hypothetical trajectories of two groups of patients through multidimensional space. Each line indicates the path taken by a single patient, with periods of
organ failure highlighted in red. A superficially similar group of patients may appear clinically indistinguishable (a), but different trajectories through illness
are revealed by informative vectors derived from high-throughput data (b). It is reasonable to expect that such biological differences in disease process will
underlie different responses to host-directed therapies.
Systems biology in infectious disease Russell and Baillie 143important similarities and differences in immune
response will become apparent [29].
Our ability to identify groups of patients sharing
therapeutically-relevant similarities is dependent on
measuring the relevant biological signal that determines
classification. This is the fundamental attraction of
high-throughput technologies e the probability of
measuring important signals is greater if more signals are
measured. That such groupings of patients, or disease
endotypes, exist is already clear: therapeutically-
important sub-classifications have recently been
discovered that redefine the clinical syndromes of
asthma [30,31], ARDS [32], and acute mountain sick-
ness [33]. In two related autoimmune conditions,
ANCA-associated vasculitis (AAV) and systemic lupus
erythematosus (SLE), a T-cell gene expression signa-
ture clearly delineates two distinct endotypes [34].
Subsequent work elucidated the immunological process
underlying this sub-classification, CD8 T-cell exhaus-
tion [35]. This process is associated with better out-
comes in autoimmune disease, but poor clearance of
viral infection. In the future it may be possible to
manipulate this pathway therapeutically in patients
with AAV or SLE, to prevent relapse, or in the opposite
direction in patients with chronic viral infection, to
promote clearance.
Therapeutic targets
Even in the best-case scenario, the distance between
the identification of a tractable therapeutic target andwww.sciencedirect.comsuccessful exploitation in clinical practice is substantial,
so it is no surprise that potential host-directed therapies
discovered through high-dimensionality analytics have
not yet been proven to be effective in clinical trials.
Nonetheless there are some promising leads, a few of
which are described here. These exemplify different
approaches: integrating cell culture, animal and human
data sequentially to identify a host anti-viral factor
(influenza virus); and using computational predictions
from transcriptional data with proteomic and genetically
modified animal studies to identify host pathways
involved in pathogenesis (SARS Coronavirus).
Influenza virus
Viruses are obligate parasites and undergo exclusively
intracellular replication; properties that make them
ideal for study in cell culture where host factors that
affect viral replication can be expected to do the same
in vivo. siRNA screening has been used as a genome-
wide approach to identify such host factors for influ-
enza virus infection. IFITM3 was identified as a novel
host anti-viral factor by siRNA screening with confir-
matory in vitro work (including exogenous interferon
administration and stable IFITM3 expression)
demonstrating it is required for an effective interferon
response to inhibit influenza virus replication [36].
Work in Ifitm3e/e mice was then undertaken,
confirming that in vivo, influenza virus-infected mice
suffer fatal viral pneumonia, even when infected with a
low-pathogenicity virus [37]. The GenISIS/MOSAIC
groups identified a single nucleotide polymorphismCurrent Opinion in Systems Biology 2017, 2:139–145
144 Cancer and systemic diseases (2017)(rs12252-C) within the IFITM3 coding region in
humans that was strongly over-represented in patients
hospitalised with influenza virus infection [37], the
majority of whom required invasive ventilation. Meta-
analysis of genomic studies of IFITM3 and influenza
virus infection has confirmed this association between
SNP rs12252-C and increased susceptibility to infec-
tion in humans [38]. Work is now underway in many
groups to investigate the impact of IFITM proteins in
antiviral defence, with a view to generating host-
targeted antiviral therapies. This example highlights
the potential of a systems-wide approach, integrating
and cross-validating results from various experimental
modalities (high-throughput screening in cell culture,
followed by targeted studies in mice and humans) to
converge from large-scale data onto a single critical host
immune factor.
SARS coronavirus
Acute lung injury (ALI) and progression to acute res-
piratory distress syndrome are major features of the
pathophysiology of SARS Coronavirus (and indeed other
respiratory virus) infection. Pathological changes in mice
are very similar to humans and there is a dose-response
relationship between viral inoculum and the severity of
ALI. Host responses to the virus that result in ALI are
poorly understood. To investigate host responses asso-
ciated with more severe acute lung injury in a murine
model of SARS Coronavirus (SARS-CoV) infection,
transcriptomic profiles of mice infected with lethal and
sub-lethal doses of virus were compared and correlated
with pathological data at multiple time points, then
subject to bioinformatic network analysis [39]. A
module of genes involved in cell adhesion, extracellular
matrix remodelling and wound healing was significantly
up-regulated in the lethal infection model, and com-
ponents of the urokinase pathway were found to be the
most enriched and differentially regulated. Mass-
spectrometry proteomic analysis was then used to
explore this transcriptional data further, demonstrating
that SARS-CoV infection resulted in increased expres-
sion of fibrin b and g chains, factor VIII and cytokeratins
(all components of hyaline membranes), and reduced
expression of surfactant proteins in the lung. These data
are consistent with histological post-mortem findings in
SARS-CoV infected humans, where extensive fibrin
exudate, extensive hyaline membrane formation and
alveolar collapse have been observed [40]. Serpine1 is
part of the urokinase pathway and contributes to ECM
remodelling. To confirm this finding from transcriptional
and proteomic studies, Serpine1e/e knockout mice
were infected with SARS-CoVand found to have a worse
outcome compared to wild type mice. This systems-
based approach to SARS-CoV, sequentially applying
transcriptional, proteomic then genetic modification
techniques, demonstrates that the urokinase pathway
contributes to ALI, thus identifying a target for futureCurrent Opinion in Systems Biology 2017, 2:139–145experimental medicine work to determine if it can be
therapeutically altered to benefit the host.Conclusion
These examples give us confidence that we can expect
more progress along similar lines as the potential of
systems medicine approaches becomes more widely
appreciated, as expertise in computational methodolo-
gies grows, and as the cost of generating relevant data
falls.
Physicians have long made progress by recognising pat-
terns of similar observations in groups of patients, and by
determining which biological features of disease are
amenable to therapy. What has changed is the unprec-
edented rate of advance in new resources and tools with
which to tackle the ancient problems of diagnosis and
therapy in infectious disease. Our responsibility is to
ensure a similar acceleration in clinical progress.
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